Astellas Korea – Jeong Hai-Do, President
The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and…
Astellas Korea
Last updated: 22.12.2014
Astellas Pharma Korea, Inc. is the Korean subsidiary of a leading global pharmaceutical company with outstanding R&D capabilities and a worldwide network.
Astellas has contributed to increasing the quality of life of customers by developing drugs to treat adult diseases and disorders such as urination disturbances common in men, frequent urination commonly in women, overactive bladder syndrome that causes frequent bathroom trips, as well as painful atopic dermatitis. The company also developed Gaster D, a gastroduodenal ulcer treatment drug, which has helped decrease the frequency of gastric ulcer surgery, and Prograf, and immunosuppression agent, which has improved the survival rate of organ transplant recipients.
Astellas Pharma Korea has been growing as a firm, taking pride in its contributions to customer quality of life, and provision of premium medicines in Korea, including Harnal, Vesicare, Prograf, and Protopic Ointment. It also a promising company in the mid-to-long term with many superb products awaiting further development, clinical testing, and launch. Astellas Pharma Korea does not aim to merely expand sales volume, but will continuously increase company value with the goal of maximizing added value for customers and thoseseeking better health, by establishing its Global Category Leader business model.
Contact details
6F 401 Hakdong-ro, Gangnam-gu, Seoul
+82 2 3448 0504
www.astellas.co.kr
Interviews
Related
Byung Guk Yang – CEO, Daewoong Bio, South Korea
Dr Byung Guk Yang, CEO of Daewoong Bio, explains the challenges the Korean healthcare system is facing and how his…
YJ Kim – Country Manager, BD Korea
YJ Kim, country manager at BD Korea, discusses the integration of Bard into BD at the local level. He also offers…
Seok Joo Lee – CEO, ISU Abxis, South Korea
ISU Abxis, a subsidiary of the ISU conglomerate, is a biotech company with a focus on orphan drugs and rare…
Sora Lee – Vice President & General Manager Korea, Syneos Health
Syneos Health, established through a merger in 2017, has held a foothold in Korea through its legacy organisations…
Jeong Woo Cho – CEO & President, SK Biopharmaceuticals & SK Life…
SK Group, the second largest conglomerate in South Korea and renowned as a leader in energy, telecommunications,…
Bong Gil Nam – Chairman & Owner, Pharmbio Korea
Bong Gil Nam, chairman and owner of Pharmbio Korea, offers his insights on his company’s importance in…
Han-Oh Park – President, Founder and CEO, Bioneer, South Korea
Bioneer, founded in 1992, lays claim to be Korea’s oldest biotechnology company. President, founder and CEO, Dr…
H. Samuel Muk – President & CEO, Korea Drug Development Fund (KDDF)
The Korea Drug Development Fund (KDDF) is a government-funded organization created to accelerate innovation…
Nam Han Cho – President, International Diabetes Federation, South Korea
Dr Nam Han Cho, president of the International Diabetes Federation (IDF) and professor of Preventive Medicine at…
Korea to Strengthen Support for Rare Disease Patients
This week, the Korean Ministry of Food and Drug Safety announced that it would enhance drug safety management and…
Korean Healthcare and Pharma’s 10-Year Plan
The administration of President Moon Jae-in is moving to ensure the enduring success of South Korea’s healthcare…
Narihiko Yoshii – President, Mitsubishi Tanabe Pharma Korea
Narihiko Yoshii, president of Mitsubishi Tanabe Pharma Korea unveils the value that they are bringing to Korean…
